project id: TCGA-BLCA; case submitter id: TCGA-LC-A66R; no matched normal low pass wgs: false; no matched normal targeted sequencing: false; no matched normal wgs: false; no matched normal wxs: false; selected normal low pass wgs: false; selected normal targeted sequencing: false; selected normal wxs: false; source center: 23; state: released; a260 a280 ratio: 1.88; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.54; rna integrity number: 7.1; age at index: 78; days to birth: -28793; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1934; age at diagnosis: 28793; ajcc clinical t: T4a; ajcc pathologic m: MX; ajcc pathologic n: N2; ajcc pathologic stage: Stage IV; ajcc pathologic t: T4a; ajcc staging system edition: 7th; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 466.0; icd 10 code: C67.9; last known disease status: not reported; morphology: 8120/3; primary diagnosis: Transitional cell carcinoma; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; site of resection or biopsy: Bladder, NOS; synchronous malignancy: No; tissue or organ of origin: Bladder, NOS; tumor grade: Not Reported; year of diagnosis: 2012; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 136; days to sample procurement: 0; initial weight: 600.0; portion submitter id: TCGA-LC-A66R-01A-41; percent lymphocyte infiltration: 13.0; percent monocyte infiltration: 0.0; percent necrosis: 3.0; percent neutrophil infiltration: 1.0; percent normal cells: 0.0; percent stromal cells: 0.0; percent tumor cells: 97.0; percent tumor nuclei: 70.0;